PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.

Journal of the National Cancer Institute
Hope S RugoLeisha A Emens

Abstract

In the Phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+nP) showed clinical benefit in advanced/metastatic triple-negative breast cancer (TNBC) patients who were programmed death-ligand 1 (PD-L1) + (tumor-infiltrating immune cells [IC] ≥1%) using the SP142 immunohistochemistry (IHC) assay. Here we evaluate 2 other PD-L1 assays for analytical concordance with SP142 and patient-associated clinical outcomes. Samples from 614 patients (68.1% of intention-to-treat population) were centrally evaluated by IHC for PD-L1 status on IC (VENTANA SP142, SP263, Dako 22C3) or as a combined positive score (CPS; 22C3). Using SP142, SP263, and 22C3 assays, PD-L1 IC ≥ 1% prevalence was 46.4% (95% confidence interval [CI] = 42.5-50.4%), 74.9% (95% CI = 71.5-78.3%), and 73.1% (95% CI = 69.6-76.6%), respectively; 80.9% were 22C3 at CPS ≥1. At IC ≥ 1% (+), the analytical concordance between SP142 and SP263 and 22C3 was 69.2% and 68.7%, respectively. Almost all SP142+ cases were captured by other assays (double positive), but several SP263 + (29.6%) or 22C3 + (29.0%) cases were SP142- (single positive). A+nP clinical activity vs placebo+nP in SP263+ and 22C3+ patients (progression-free survival [PFS] hazard ratios [HRs] = 0.64-0.68; o...Continue Reading

References

Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Aug 28, 2017·Human Pathology·Tejashree KarnikOssama Tawfik
Nov 28, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shona HendryStephen B Fox
Jan 19, 2018·Applied Immunohistochemistry & Molecular Morphology : AIMM·Bharathi VennapusaZachary Boyd
May 26, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ming Sound TsaoFred R Hirsch
Oct 10, 2018·Proceedings of the National Academy of Sciences of the United States of America·Marcin KowanetzPriti S Hegde
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Nov 27, 2018·Expert Opinion on Investigational Drugs·Anne-Sophie Heimes, Marcus Schmidt
Feb 15, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Dennis P O'MalleyLawrence M Weiss
May 10, 2019·BMC Medicine·Antonio MarraGiuseppe Curigliano
Aug 7, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Emina TorlakovicMing-Sound Tsao
Feb 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ScottH Al-Masri
Feb 27, 2020·The New England Journal of Medicine·Peter SchmidUNKNOWN KEYNOTE-522 Investigators
Apr 18, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Emily S ReisenbichlerDavid L Rimm
Oct 1, 2020·The New England Journal of Medicine·Roy S HerbstDavid R Spigel

❮ Previous
Next ❯

Citations

Jul 20, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Yinxing ZhuWenwen Zhang
Jun 8, 2021·Journal of the National Cancer Institute·Niki GavrielatouDavid L Rimm
Sep 12, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sandra Martinez-MorillaDavid L Rimm
Nov 19, 2021·Expert Opinion on Investigational Drugs·Alessandro Rizzo, Angela Dalia Ricci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.